MarketCap
Facebook
X
TelegramAnnual report 2025
added 11-19-2025
Enanta Pharmaceuticals Cash and Cash Equivalents 2011-2026 | ENTA
Annual Cash and Cash Equivalents Enanta Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 32.3 M | 37.2 M | 85.4 M | 44 M | 57.2 M | 87.1 M | 51.2 M | 63.9 M | 65.7 M | 16.6 M | 21.7 M | 30.7 M | 8.86 M | 10.5 M | 6.84 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 87.1 M | 6.84 M | 41.3 M |
Quarterly Cash and Cash Equivalents Enanta Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 44.8 M | 60.2 M | 84.3 M | 37.2 M | 35.8 M | 63.5 M | 39.9 M | 85.4 M | 95.2 M | 73.2 M | 42.2 M | 44 M | 28.4 M | 41 M | 99.1 M | 57.2 M | 4.6 M | 57.2 M | 55.1 M | 87.1 M | 87.1 M | 87.1 M | 27.6 M | 51.2 M | 51.2 M | 51.2 M | 74.4 M | 63.9 M | 63.9 M | 63.9 M | 68.1 M | 65.7 M | 65.7 M | 65.7 M | 20.6 M | 16.6 M | 16.6 M | 20.6 M | 46.2 M | 21.7 M | 21.7 M | 46.2 M | 34.1 M | 30.7 M | 30.7 M | 34.1 M | 4.43 M | 8.86 M | 8.86 M | 4.43 M | 20.7 M | 10.5 M | 10.5 M | 20.7 M | - | 6.84 M | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 99.1 M | 4.43 M | 44.7 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
75.2 M | $ 1.65 | 7.91 % | $ 92.9 M |  China |
 |
AstraZeneca PLC
AZN
|
5.49 B | $ 93.52 | -1.2 % | $ 96.9 B |  Britain |
 |
Autolus Therapeutics plc
AUTL
|
240 M | $ 1.52 | -16.3 % | $ 388 M | Britain |
 |
Alterity Therapeutics Limited
ATHE
|
34.8 M | $ 3.59 | 1.99 % | $ 8.64 B |  Australia |
 |
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K |  USA |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Biogen
BIIB
|
2.38 B | $ 184.48 | -1.67 % | $ 26.9 B | USA |
 |
BioNTech SE
BNTX
|
9.76 B | $ 102.17 | 2.32 % | $ 27.2 B | Germany |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 4.25 | 1.67 % | $ 9.25 B |  Israel |
 |
Ascendis Pharma A/S
ASND
|
560 M | $ 207.49 | 2.22 % | $ 5 B |  Danmark |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M |  Canada |
 |
Catalyst Biosciences
CBIO
|
33.5 M | $ 10.84 | 0.46 % | $ 714 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
144 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Corcept Therapeutics Incorporated
CORT
|
128 M | $ 37.35 | -0.4 % | $ 3.86 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
89.4 M | - | - | $ 1.01 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
518 M | $ 23.18 | 2.02 % | $ 2.75 B | USA |
 |
AIkido Pharma
AIKI
|
4.08 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
Celldex Therapeutics
CLDX
|
28.4 M | $ 25.59 | -6.54 % | $ 1.65 M | USA |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
118 M | - | 4.14 % | $ 49.1 M | USA |
 |
Cellectis S.A.
CLLS
|
143 M | $ 4.22 | -4.2 % | $ 116 M | France |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | Israel |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
152 M | $ 29.43 | 6.09 % | $ 1.43 B | USA |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
Brickell Biotech
BBI
|
10.9 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
322 M | $ 9.66 | 2.28 % | $ 1.53 B | Britain |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
220 M | - | -6.81 % | $ 3.04 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
227 M | $ 66.05 | 2.3 % | $ 8.83 B | USA |
 |
Athersys
ATHX
|
37.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.59 M | - | -52.27 % | $ 4.45 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
265 M | $ 55.11 | 3.49 % | $ 4.45 B | USA |
 |
Abeona Therapeutics
ABEO
|
14.5 M | $ 5.14 | -1.06 % | $ 110 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
298 M | $ 55.17 | 2.47 % | $ 4.65 B |  Schweiz |
 |
AVROBIO
AVRO
|
98 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
455 M | $ 632.29 | 0.09 % | $ 47.9 B | USA |
 |
ADiTx Therapeutics
ADTX
|
833 K | $ 0.81 | 1.96 % | $ 10.7 K | USA |
 |
Aytu BioScience
AYTU
|
31 M | $ 2.7 | 2.27 % | $ 17 M | USA |